Tuesday, 28 July 2009

PacificGMP will provide development and manufacturing services for the University of Southern California


SAFC orders boosted by H1N1

Sales at Sigma-Aldrich's fine chemicals business, SAFC, declined 14% in Q2 2009. The company said sales improved in Q2 against Q1, but were weak compared to 2008. The SAFC saw increased booked orders for future delivery, rising 19% in Q2 to an all-time high, some of which are for H1N1 related products. The company expects SAFC to make a modest overall contribution to its low single-digit organic growth expectations for 2009.
Seeking Alpha

Albemarle sees fine chemicals income decline 80%

Albemarle's Fine Chemicals business saw sales decline 32% to $104m in Q2 2009, and income decline from $24.5m to $5.2m. The company attributed the declines to reduced sales and production volumes but is encouraged by a strong new product pipeline for the second half of the year.

Thursday, 23 July 2009

Cambridge Major to open new API facility

Cambridge Major Laboratories will inaugurate its new API plant in Gemantown, WI, next week. The facility, which will become operational during August, will allow the company to provide large scale production for its customers.
Milwaukee and Southeastern Wisconsin Business News

Tuesday, 21 July 2009

Almac receives MHRA licence for GMP radiolabeling service


Fine chems first quarter positive for Johnson Matthey

Johnson Matthey says its Fine Chemicals Division was well ahead of last year in the first quarter. The company said demand has been less affected by the recession than some other business units and it has generated income from the generic version of Adderal XR, launched in April.
Easy Bourse

Lonza consolidates custom manufacturing operations

Lonza has brought its fine chemical and biopharmaceutical custom manufacturing operations together into a single business unit. The Lonza Custom Manufacturing unit is designed to help the company's sales and marketing activities.
Easy Bourse

The Informex USA show has been rebranded into two segments: Informex Pharma and Informex Specialty


SynCo Bio Partners has increased its capacity through addition to quality team

SynCo Bio Partners

Sunday, 19 July 2009

The Food and Drug Administration hopes to build closer ties with the European Medicines Agency


Lonza is being investigated by the Swiss stock exchange over possible breaches in its reporting obligations

Mondo Visione

Lonza will manufacture LFB's anti-RhD antibody


Senate committee vote on biosimilars

The US Senate Health, Education, Labor and Pensions Committee has approved an amendment that would provide innovative biologic drugs with 12 years protection from competition by biosimilar products.
Wall Street Journal

Sunday, 5 July 2009

Wednesday, 1 July 2009

Lonza in contract dispute with Altus

Altus Pharmaceuticals has terminated a supply agreement with Lonza citing an alleged breach in the manufacture and supply of key ingredients. The move follows Lonza suing Altus over accusations that the contract was terminated in violation of certain covenants.
Boston Business Journal

Hovione's API plant in Macau has passed an FDA pre-approval inspection

Pharmaceutical Technology Europe

Cobra Biomanufacturing saw revenues rise 62%, margins rise 46% and losses fall in the six months ended 31 March 2009